Table 1

Baseline characteristics of the COVID-19 cases

Total (N=113)
Male, n (%)70 (61.9)
Age at symptoms (years)
 Median (IQR)58 (53–63)
Age class at symptoms (years), n(%)
 ≤5023 (20.4)
 50–6043 (38.1)
 >6047 (41.6)
Location of patient at occurrence of symptoms, n(%)
 Home75 (67)
 Hospital35 (31.3)
 On arrival for LT2 (1.8)
 Missing1
Indication for LT, n (%)
 Decompensated cirrhosis with or without HCC*77 (68.1)
 HCC20 (17.7)
 Other†16 (14.2)
Aetiology, n (%)
 Alcohol30 (26.5)
 Alcohol+NASH8 (7.1)
 Alcohol+HCV active or inactive5 (4.4)
 AIH+PBC+PSC17 (15)
 HBV12 (10.6)
 HCV active or inactive9 (8)
 NASH8 (7.1)
 Other24 (21.2)
Comorbidities,N(%)
 No29 (25.7)
 Diabetes mellitus45 (39.8)
 Arterial hypertension26 (23)
 BMI>30 kg/m223 (20.4)
 Current or former tobacco smoker18 (15.9)
 Kidney function impairment‡12 (10.6)
 Chronic obstructive lung disease5 (4.4)
 Coronary artery disease4 (3.5)
 Other6 (5.3)
Number of comorbidities class, n (%)
 029 (25.7)
 146 (40.7)
 224 (21.2)
 ≥314 (12.4)
Drugs, n (%)
 No63 (55.8)
 Beta blockers37 (32.7)
 ACE inhibitors or angiotensin II receptor antagonists7 (6.2)
 Beta blockers+ACE inhibitors6 (5.3)
MELD score pre-COVID-19, n (%)
 Median (IQR)16 (11–21)
 <1542 (37.2)
 15–1934 (30.1)
 ≥2037 (32.7)
Child-Pugh score pre-COVID-19,§ n (%)
 Median (IQR)8 (7–10)
 5–625 (23.6)
 7–942 (39.6)
 ≥1039 (36.8)
 Missing1
International Norm INR pre-COVID-19
 Median (IQR)1.4 (1.2–1.8)
Bilirubin (mg/dL) pre-COVID-19
 Median (IQR)2.7 (1–8)
Creatinine (mg/dL) pre-COVID-19
 Median (IQR)0.9 (0.8–1.3)
Ascites pre-COVID-19,§ n (%)
 0=no34 (32.7)
 1=only at ultrasound17 (16.3)
 2=moderate32 (30.8)
 3=severe or tense ascites6 (5.8)
 4=refractory15 (14.4)
 Missing3
Hepatic encephalopathy pre-COVID-19,§ n (%)
 1=absent81 (77.9)
 2=grades 1–221 (20.2)
 3=grades 3–42 (1.9)
 Missing3
  • Pre-COVID-19 denotes most recent value before symptoms.

  • *72 of 77 patients without HCC and 5 of 77 with HCC.

  • †Re-LT for chronic rejection or hepatic artery thrombosis; autosomal dominant polycystic liver disease; neuroendocrine tumour; primary sclerosing cholangitis; surgical biliary complication.

  • ‡P-creatinine >2 mg/dL

  • §6 patients without cirrhosis were excluded.

  • AIH, autoimmune hepatitis; BMI, Body Mass Index; HCC, hepatocellular carcinoma; INR, international normalised ratio; LT, liver transplant; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.